The company said it could buy back senior notes, shares or other securities under the new program, which will begin on Nov. 21, the same day its old program ends. The announcement comes a few days after acquisition-hungry Valeant's $54 billion offer to buy Botox maker Allergan Inc "Valeant's board of directors believes that the proposed purchases are in the best interests of the company and are a desirable use of corporate funds," the company said in a statement on Thursday.